CompuMed
This article was originally published in The Gray Sheet
Executive Summary
Inks deal with Merck & Co. under which it gains rights to incorporate OsteoGram software enhancements developed by Merck into the digital OsteoView 2000 bone densitometer, which is under development at CompuMed and intended for use in detecting osteoporosis and arthritis. In March, CompuMed regained exclusive worldwide rights to the OsteoGram bone density test after licensing them to Merck in 1995 ("The Gray Sheet" Sept. 4, 1995, In Brief). Merck has "invested substantial resources" in the assets related to OsteoGram, CompuMed says, including software enhancements, laboratory equipment, regulatory and clinical work products, intellectual property rights, copyrights, trademarks, marketing materials and artwork, all of which are covered under the agreement...